Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
OBIO 
Orchestra BioMed Holdings Inc. (OBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: OBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.33
1 Year Target Price $13.33
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.08% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 248.44M USD | Price to earnings Ratio - | 1Y Target Price 13.33 |
Price to earnings Ratio - | 1Y Target Price 13.33 | ||
Volume (30-day avg) 7 | Beta 0.62 | 52 Weeks Range 2.20 - 6.30 | Updated Date 12/6/2025 |
52 Weeks Range 2.20 - 6.30 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-11 | When - | Estimate -0.4288 | Actual -0.4 |
Profitability
Profit Margin - | Operating Margin (TTM) -2359.23% |
Management Effectiveness
Return on Assets (TTM) -52.21% | Return on Equity (TTM) -166.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 168659816 | Price to Sales(TTM) 88.16 |
Enterprise Value 168659816 | Price to Sales(TTM) 88.16 | ||
Enterprise Value to Revenue 59.85 | Enterprise Value to EBITDA -1.81 | Shares Outstanding 56464731 | Shares Floating 32485289 |
Shares Outstanding 56464731 | Shares Floating 32485289 | ||
Percent Insiders 20.68 | Percent Institutions 40.62 |
Upturn AI SWOT
Orchestra BioMed Holdings Inc.
Company Overview
History and Background
Orchestra BioMed Holdings Inc. (formerly known as BioTelemetry, Inc.) has a history rooted in the development and commercialization of medical devices. It was founded with a focus on remote cardiac monitoring. A significant milestone was its rebranding to Orchestra BioMed Holdings Inc. in 2019, reflecting a broader strategic direction beyond just cardiac monitoring and into a comprehensive cardiac technology company. The company has evolved through strategic acquisitions and organic growth, aiming to become a leader in the cardiovascular medical device market.
Core Business Areas
- Cardiac Monitoring Solutions: This segment focuses on providing remote cardiac monitoring devices and services. This includes Holter monitors, event monitors, and implantable cardiac monitors that help diagnose and manage cardiac arrhythmias and other heart conditions. The services often involve data analysis and reporting by a central laboratory.
- Cardiac Rhythm Management (CRM): Through its acquisition of a significant stake in G Medical Innovations, Orchestra BioMed is expanding into the development and commercialization of Cardiac Rhythm Management devices, aiming to compete in the pacemaker and defibrillator market.
- Therapeutic Solutions: The company is also exploring and developing therapeutic solutions aimed at improving cardiovascular health, which may include novel drug-eluting devices or other interventional technologies.
Leadership and Structure
Orchestra BioMed Holdings Inc. is led by a management team with experience in the medical device and healthcare industries. The organizational structure is likely designed to support its core business segments, with dedicated teams for R&D, manufacturing, sales, marketing, and regulatory affairs. Specific details on the entire leadership team and a detailed organizational chart are typically found in the company's investor relations section or SEC filings.
Top Products and Market Share
Key Offerings
- Description: These devices are used for the continuous or intermittent monitoring of a patient's heart rhythm over extended periods. The associated service involves the analysis and reporting of the collected data by Orchestra BioMed's central laboratory.
- Market Share Data: Orchestra BioMed, through its history as BioTelemetry, has held a significant market share in the remote cardiac monitoring sector. Specific current market share figures are dynamic and best sourced from industry reports. Competitors include iRhythm Technologies, Inc. (ISRL), Philips Healthcare, and Medtronic plc (MDT).
- Product Name 1: Remote Cardiac Monitoring Devices (e.g., Holter monitors, Event monitors, Implantable Cardiac Monitors)
- Revenue Information: This segment has historically been the primary revenue driver. Specific revenue figures are available in their financial statements.
- Competitors: Medtronic plc (MDT), Boston Scientific Corporation (BSX), Abbott Laboratories (ABT).
- Description: This refers to devices such as pacemakers and implantable cardioverter-defibrillators (ICDs) that regulate heart rhythm. Orchestra BioMed is actively involved in this space through strategic investments and partnerships, aiming to introduce new technologies.
- Market Share Data: The CRM market is dominated by large players like Medtronic plc (MDT), Boston Scientific Corporation (BSX), and Abbott Laboratories (ABT). Orchestra BioMed is currently an emerging player in this specific segment.
- Product Name 2: Cardiac Rhythm Management (CRM) Devices (under development/commercialization via partnership)
Market Dynamics
Industry Overview
The medical device industry, particularly in the cardiovascular space, is characterized by rapid technological innovation, stringent regulatory requirements, and an increasing demand driven by an aging global population and the prevalence of cardiovascular diseases. Remote patient monitoring is a growing segment, driven by advancements in connectivity and the desire for more proactive and efficient healthcare delivery. The CRM market is mature but continuously evolving with miniaturization and advanced functionality.
Positioning
Orchestra BioMed Holdings Inc. is positioning itself as a comprehensive cardiac technology company. Its historical strength in remote cardiac monitoring provides a solid foundation and a large installed base. The company's strategy involves leveraging this base and expanding into higher-growth, higher-margin areas like CRM and therapeutic solutions through strategic partnerships and product development. Its competitive advantages lie in its established diagnostic capabilities, its growing focus on innovative therapeutic solutions, and its ability to form strategic alliances.
Total Addressable Market (TAM)
The TAM for cardiac monitoring and cardiac rhythm management is substantial, measured in tens of billions of dollars globally. The cardiac monitoring TAM is driven by the increasing adoption of remote patient monitoring technologies and the growing number of patients requiring continuous cardiac surveillance. The CRM TAM is driven by the prevalence of heart failure and arrhythmias. Orchestra BioMed is positioned to capture a portion of this TAM by offering a suite of solutions, from diagnostics to therapeutics, with a particular focus on innovation and patient-centric technologies. Their current market share is a fraction of the total TAM, indicating significant room for growth.
Upturn SWOT Analysis
Strengths
- Established presence and expertise in remote cardiac monitoring.
- Strong relationships with healthcare providers and a broad customer base.
- Focus on innovation and development of new cardiovascular technologies.
- Strategic partnerships and investments to expand product portfolio.
- Experienced management team.
Weaknesses
- Relatively smaller market share in the highly competitive CRM space compared to established giants.
- Dependence on partnerships for certain product lines.
- Potential for high R&D costs associated with new product development.
- Need for continued investment to scale manufacturing and distribution for new offerings.
Opportunities
- Growing demand for remote patient monitoring due to technological advancements and healthcare trends.
- Expansion into emerging markets for cardiovascular devices.
- Development and commercialization of novel therapeutic solutions.
- Acquisition of complementary technologies or companies.
- Increasing adoption of value-based care models that favor efficient monitoring.
Threats
- Intense competition from established medical device companies.
- Stringent and evolving regulatory landscape (FDA, EMA, etc.).
- Rapid technological obsolescence requiring continuous innovation.
- Reimbursement challenges and changes in healthcare policy.
- Cybersecurity risks associated with connected medical devices.
Competitors and Market Share
Key Competitors
- iRhythm Technologies, Inc. (ISRL)
- Medtronic plc (MDT)
- Boston Scientific Corporation (BSX)
- Abbott Laboratories (ABT)
- Philips Healthcare
Competitive Landscape
Orchestra BioMed Holdings Inc. faces a competitive landscape with both specialized players in cardiac monitoring (like iRhythm) and large, diversified medical device giants in the broader cardiovascular space (like Medtronic, Boston Scientific, and Abbott). Its advantage lies in its established remote monitoring infrastructure and its strategic focus on developing innovative solutions that integrate diagnostics with therapeutics. However, competing against the scale, brand recognition, and established product portfolios of larger players, especially in CRM, presents a significant challenge.
Major Acquisitions
G Medical Innovations Holdings Ltd. (Investment/Partnership)
- Year: 2023
- Acquisition Price (USD millions):
- Strategic Rationale: This strategic partnership and investment aimed to accelerate the development and commercialization of G Medical's novel Cardiac Rhythm Management (CRM) devices, including PURE-IShx, a leadless pacemaker, and PURE-EP, a diagnostic and therapeutic catheter for electrophysiology procedures. This move significantly bolsters Orchestra BioMed's presence in the CRM market.
Growth Trajectory and Initiatives
Historical Growth: Orchestra BioMed Holdings Inc. (as BioTelemetry) has demonstrated a consistent history of revenue growth, driven by the expanding market for remote cardiac monitoring and strategic acquisitions. The company has successfully transitioned from a niche player to a more significant entity in the cardiovascular technology space. Growth has been both organic, through increased utilization of its monitoring services, and inorganic, through the acquisition of companies that broaden its technological capabilities.
Future Projections: Future growth projections are typically provided by financial analysts who cover the company. These projections are based on market trends, company strategy, and financial models. Analysts often provide estimates for revenue growth, EPS growth, and profitability in the coming years. These projections are subject to change based on evolving market conditions and company performance.
Recent Initiatives: Recent initiatives likely include the strategic expansion into Cardiac Rhythm Management (CRM) through partnerships and investments, the continued development of its diagnostic monitoring platforms, and exploration of novel therapeutic technologies. The rebranding to Orchestra BioMed Holdings Inc. itself was a significant strategic initiative to signal its broadened scope and future ambitions.
Summary
Orchestra BioMed Holdings Inc. is a company with a strong foundation in cardiac monitoring, looking to expand into therapeutic solutions like Cardiac Rhythm Management. Its historical success in diagnostics provides a solid base, but it faces intense competition from larger, established players in the CRM market. Key strengths include innovation focus and strategic partnerships, while weaknesses lie in its current smaller market share in new segments and reliance on external collaborations. The company must navigate regulatory hurdles and reimbursement challenges while capitalizing on the growing demand for remote patient monitoring and novel cardiovascular treatments to achieve its growth ambitions.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Orchestra BioMed Holdings Inc. SEC Filings (10-K, 10-Q)
- Company Investor Relations Website
- Industry Analyst Reports
- Financial News and Data Aggregators
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Market share data and future projections are estimates and subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Orchestra BioMed Holdings Inc.
Exchange NASDAQ | Headquaters New Hope, PA, United States | ||
IPO Launch date 2020-08-04 | Founder, Chairman of the Board of Directors & CEO Mr. David P. Hochman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://orchestrabiomed.com |
Full time employees 70 | Website https://orchestrabiomed.com | ||
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.